Abstract
The epidermal growth factor receptor (EGFR) is a membrane-anchored, 170 kDa, protein tyrosine kinase that has been implicated in tumorigenesis. Recent sequence data from the publicly funded Human Genome Project has led to a revision in the structure of the EGFR gene, as well as an improved understanding of its mutations in tumor cells. The exons and introns of the EGFR gene are contained within 168 kilobases of DNA, including a completely sequenced 123-kilobase first intron. The EGFR gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion (DM) and tandem duplication (TDM) mutants. The most common mutant is EGFRvIII, which arises from recombination between introns 1 and 7 with deletion of intervening sequences. Some human gliomas express 185 kDa and 190 kDa EGFR tandem duplication mutants with constitutive functional activity. These tumors contain EGFR genes with an in-frame tandem duplication of exons 18 through 25 or exons 18 through 26 respectively. Th e TDM also arise from recombination between flanking introns 17 and either 25 or 26. DM and TDM have been found in the same tumors, suggesting that the mechanisms responsible for both types of mutants may be closely related. Each of the introns involved in tumor-specific recombination contain sequences with homology to the recombination signal sequence (RSS) heptamers present in the V(D)J region of the immunoglobulin and T lymphocyte antigen receptor genes. These observations suggest a possible mechanism for oncogenic EGFR gene recombination in malignant gliomas.
Current Genomics
Title: Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Volume: 4 Issue: 1
Author(s): Michael J. Ciesielski and Robert A. Fenstermaker
Affiliation:
Abstract: The epidermal growth factor receptor (EGFR) is a membrane-anchored, 170 kDa, protein tyrosine kinase that has been implicated in tumorigenesis. Recent sequence data from the publicly funded Human Genome Project has led to a revision in the structure of the EGFR gene, as well as an improved understanding of its mutations in tumor cells. The exons and introns of the EGFR gene are contained within 168 kilobases of DNA, including a completely sequenced 123-kilobase first intron. The EGFR gene is frequently amplified and rearranged in malignant gliomas with expression of oncogenic deletion (DM) and tandem duplication (TDM) mutants. The most common mutant is EGFRvIII, which arises from recombination between introns 1 and 7 with deletion of intervening sequences. Some human gliomas express 185 kDa and 190 kDa EGFR tandem duplication mutants with constitutive functional activity. These tumors contain EGFR genes with an in-frame tandem duplication of exons 18 through 25 or exons 18 through 26 respectively. Th e TDM also arise from recombination between flanking introns 17 and either 25 or 26. DM and TDM have been found in the same tumors, suggesting that the mechanisms responsible for both types of mutants may be closely related. Each of the introns involved in tumor-specific recombination contain sequences with homology to the recombination signal sequence (RSS) heptamers present in the V(D)J region of the immunoglobulin and T lymphocyte antigen receptor genes. These observations suggest a possible mechanism for oncogenic EGFR gene recombination in malignant gliomas.
Export Options
About this article
Cite this article as:
Ciesielski J. Michael and Fenstermaker A. Robert, Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas, Current Genomics 2003; 4 (1) . https://dx.doi.org/10.2174/1389202033350092
DOI https://dx.doi.org/10.2174/1389202033350092 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Towards Drug Discovery for Brain Tumours: Interaction of Kinins and Tumours at the Blood Brain Barrier Interface
Recent Patents on CNS Drug Discovery (Discontinued) Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Current Cancer Drug Targets Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Current Pharmaceutical Design Oligonucleotide Aptamers for Glioma Targeting: An Update
Central Nervous System Agents in Medicinal Chemistry Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets 1-Cyclohexylpiperazine and 3,3-Dimethylpiperidine Derivatives as Sigma-1 (σ1) and Sigma-2 (σ2) Receptor Ligands: A Review
Central Nervous System Agents in Medicinal Chemistry Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design